Shionogi is a pharmaceutical company based in Japan that specializes in research, development, manufacturing, and marketing of pharmaceutical products. Founded in 1878 as a small pharmacy in Osaka, Shionogi has grown into a well-established global pharmaceutical company. It was initially known as Shionogi Shoten and has expanded its operations over the years to become one of Japan's leading pharmaceutical companies.

The company's headquarters are located in Osaka, Japan. It operates through various subsidiaries, including Shionogi Inc. Shionogi also has research and development centers in Osaka, as well as in other countries worldwide.

Shionogi offers a wide range of products and services across various therapeutic areas, including infectious diseases, pain management, cardiovascular diseases, and oncology. Some of its notable products include Crestor, a cholesterol-lowering medication, and Mulpleta, a drug used to treat chronic liver disease. On a global scale, Shionogi operates in more than 60 countries and has established joint ventures and partnerships with other pharmaceutical companies to enhance its presence and reach in key markets.

For instance, Shionogi has collaborated with ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer, to develop and commercialize innovative HIV treatments. In terms of market position, Shionogi has made significant strides in recent years. As of the latest available data, the company generated global sales of approximately $3.

9 billion. It has positioned itself as a global player with a strong focus on research and development, aiming to address unmet medical needs and improve patient outcomes. Shionogi has achieved various milestones and received recognition for its contributions to the pharmaceutical industry.

In 2019, the company received approval from the US Food and Drug Administration for its innovative antibiotic, Fetroja, to treat urinary tract infections. This achievement reflects Shionogi's commitment to developing novel therapies. As of the latest update, Shionogi continues to focus on innovation, research, and development to create new pharmaceutical products that benefit patients worldwide.

The company is actively expanding its global presence through strategic partnerships and investments in research and development capabilities. Overall, Shionogi has established itself as a prominent pharmaceutical company with a strong global presence, a diverse product portfolio, and a commitment to improving patient health outcomes through innovative therapies and advancements in medical science